Dallas, Texas – February 27, 2026 – InterAct Therapeutics, Inc. today announced the successful completion of an INTERACT meeting with the U.S. Food and Drug Administration (FDA) for its lead program, IAT-S2. The INTERACT meeting focused on the overall development strategy for IAT-S2, including Chemistry, Manufacturing and Controls (CMC), nonclinical studies, and the proposed clinical approach. Based on the discussion, the FDA provided constructive feedback supporting InterAct’s proposed development plan, including alignment on key elements of the nonclinical and regulatory strategy to advance IAT-S2 toward an Investigational New Drug (IND) submission.
 

IAT-S2 is an AAV8-based gene therapy designed to target hepatocytes and modulate the liver microenvironment in patients with breast cancer liver metastases (BCLM), a population with significant unmet medical need. InterAct plans to continue advancing IAT-S2 through IND-enabling activities with the goal of initiating first-in-human clinical studies.

About InterAct Therapeutics
InterAct Therapeutics is a biotechnology company focused on developing first-in-class therapies that target the biology of metastatic disease by modulating organ-specific microenvironments.